Compare Enveric Biosciences Inc (ENVB) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wahed FTSE USA Shariah ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Wahed FTSE USA Shariah ETF trades at $76.99 (market cap $1.00B). The key difference: Wahed FTSE USA Shariah ETF is far larger — about 149.5× Enveric Biosciences Inc's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Wahed FTSE USA Shariah ETF for 65 Days on average.
| ENVB | HLAL | |
|---|---|---|
Market Cap | $6.69M | $1.00B |
Volume | 41,141 | 46,617 |
Sector | Health | Sector/Thematic |
52-Week High | $10.80 | $76.54 |
52-Week Low | $1.27 | $57.46 |
Typical Hold Time | 14 Days | 65 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
HLAL trades at $76.44, down 0.13% with limited daily movement. The technical picture shows bullish momentum with strong moving average support, though RSI levels above 70 indicate potential overbought conditions. Support and resistance cluster tightly around $76-77, suggesting a critical price zone. Recent corporate actions include a $0.10 dividend scheduled for September 2026.
The stock faces valuation uncertainty with key financial ratios unavailable, requiring deeper fundamental analysis. Technical strength supports near-term upside, but overbought signals and lack of current financial metrics present investment challenges. Investors need updated earnings reports and analyst coverage to assess the company's financial health and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
